Hyundai ADM Bio Inc.

Targeted disruption of Oncogenic Biosphere: A Paradigm Shift Beyond Cancer Cell-Centric Therapies | bioRxiv

Pseudo-resistance to anticancer drugs

The Next Generation COVID-19 Antiviral; Niclosamide-Based Inorganic Nanohybrid System Kills SARS-CoV-2

A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19 - Nature Communications

Hyundai ADM Bio | Company Website

Hyundai ADM Bio | LinkedIn

Hyundai Bioscience | Company Website

Hyundai Bioscience | LinkedIn

Youtube